Friday 7 November 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Bipartisan group of US Congressmen introduce bill to fight brain-related illness

Bipartisan group of US Congressmen introduce bill to fight brain-related illness

18 May 2008

A bipartisan team of prominent members of both US houses of Congress have introduced the National Neurotechnology Initiative (NNTI) Act, a bill designed to foster novel discoveries and accelerate the development of new and safer treatments for the one in three Americans living with a brain-related illness, injury or disease.

Championing the NNTI, Senators Pete Domenici (Republican, New Mexico) and Patty Murray (Democrat, Washington State) and Representatives Patrick Kennedy (D-Rhode Island 1st) and Ileana Ros-Lehtinen (R-Florida 18th) have called upon Congress to reverse the growing economic burden generated by brain-related illness, which has reached $1,300.0 billion a year in the USA due to health care costs and lost income.

"The sheer numbers speak for themselves: There are 100 million Americans suffering from a brain-related illness, with an enormous economic burden that continues to grow as the population ages," said Zack Lynch, executive director of the Neurotechnology Industry Organization, commenting on the initiative. "For a modest investment, Congress has the opportunity to streamline research efforts, accelerate the development of new treatments, promote innovation by small businesses and have a meaningful impact on the lives of those suffering from devastating diseases and injuries," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

AstraZeneca boosted by better-than-estimated growth
Pharmaceutical
AstraZeneca boosted by better-than-estimated growth
6 November 2025
Biosimilars
Samsung Bioepis settlement with J&J for Pyzchiva in Europe
6 November 2025
Biotechnology
Ultragenyx sells portion of Crysvita royalties for $400 million
6 November 2025
Biotechnology
MoonLake seeks to add $75 million to sonelokimab fund
6 November 2025
Pharmaceutical
Russia to allocate $1.72 billion annually for procurements of anti-cancer drugs
6 November 2025
Biotechnology
Moderna sales down 45% but beat expectations
6 November 2025
Biotechnology
Strand strengthens team for programmable mRNA push
6 November 2025

Company Spotlight

Viridian Therapeutics
A biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze